Dapagliflozin: A Review in Type 1 Diabetes
Oral dapagliflozin (Edistride®, Forxiga®) is approved in the EU at a dosage of 5 mg/day as an adjunct to insulin in adults with type 1 diabetes (T1D) and a body mass index (BMI) of ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. As a highly selective SGLT2 inhibitor, dapagliflozin decreases plasma glucose levels independently of insulin action and enables glycaemic control improvement without increasing the risks associated with intensive insulin therapy. In the phase III DEPICT-1 and -2 trials, dapagliflozin 5 mg/day as an adjunct to insulin improved glycaemic control and reduced total daily insulin dose and bodyweight relative to placebo in adults with inadequately controlled T1D, including in patients with a BMI of ≥ 27 kg/m2, over 24 weeks of treatment. In extensions of these trials, these improvements were maintained up to 52 weeks. Dapagliflozin was generally well tolerated with a manageable safety profile and a hypoglycaemia profile generally similar to placebo. The incidence of diabetic ketoacidosis with dapagliflozin in patients with a BMI ≥ 27 kg/m2 was less than half that of the overall population who received dapagliflozin. Dapagliflozin is the first SGLT2 inhibitor to be approved for use in T1D and, while further clinical experience in T1D is required to more definitively establish its efficacy and safety profile, it provides a promising adjunctive treatment option for adults with T1D and a BMI of ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.
During the peer review process, the manufacturer of dapagliflozin was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Julia Paik and Hannah Blair are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.
- 1.National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. 2016. https://www.nice.org.uk/guidance/ng17. Accessed 27 Sep 2019.
- 3.Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971–8.Google Scholar
- 11.European Medicines Agency. Dapagliflozin (Edistride): summary of product characteristics. 2019. http://ec.europa.eu/. Accessed 27 Sep 2019.
- 14.Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864–76.CrossRefGoogle Scholar
- 16.Mathieu C, Dandona P, Philip M, et al. Analysis of benefit/risk in the subgroup of patients with BMI of ≥ 27 kg/m2 in the dapagliflozin DEPICT-1 and -2 trials in type 1 diabetes [abstract no. SAT-LB025]. In: Endocrine Society Annual Meeting. 2019.Google Scholar
- 17.European Medicines Agency. Dapagliflozin (Forxiga/Edistride): public assessment report. 2019. https://www.ema.europa.eu/. Accessed 27 Sep 2019.
- 19.Rudofsky G, Mathieu C, Dandona P, et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type I diabetes: the DEPICT-2 study [abstract]. In: International Congress of Endocrinology. 2018.Google Scholar
- 20.Dandona P, Thoren F, Langkilde AM, et al. Pooled data analysis of composite endpoints from the DEPICT-1 and DEPICT-2 studies using dapagliflozin compared to placebo added to adjustable insulin in type 1 diabetes [abstract no. 612]. Diabetologia. 2018;61 (Suppl 1):S296.Google Scholar
- 21.Mathieu C, Dandona P, Phillip M, et al. Glucose variables in T1D studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and 2 [abstract no. 125-LB plus poster]. Diabetes. 2018;67(Suppl 1):LB35.Google Scholar
- 23.Handelsman Y, Dandona P, Mathieu C, et al. Dapagliflozin treatment reduces glycemic variability as assessed by standard deviation of interstitial glucose [abstract no. 32 plus poster]. In: AACE 28th Annual Congress. 2019.Google Scholar
- 24.Gordon J, Danne T, Beresford-Hulme LM, et al. Discontinuation of dapagliflozin in DEPICT-1 and DEPICT-2 led to clinically meaningful increases in HbA1c and body weight [abstract no. 2355-PUB]. In: ADA 79th Scientific Sessions. 2019.Google Scholar
- 25.Dandona P, Mathieu C, Phillip M, et al. Dapagliflozin (DAPA) in type 1 diabetes (T1D): pooled outcomes from DEPICT-1 and -2 [abstract no. 1231-P plus poster]. Diabetes. 2019;68(Suppl 1).Google Scholar
- 26.Rudofsky G. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-2 study. Oral presentation (International Congress of Endocrinology). 2018.Google Scholar
- 27.Edelman S, Jendle J, Dandona P, et al. Effect of adding dapagliflozin as an adjunct to insulin on urinary albumin-to-creatinine ratio over 52 weeks in adults with type 1 diabetes [abstract no. TH-PO1156 plus poster]. In: ASN Kidney Week. 2018.Google Scholar
- 29.Mathieu C, Dandona P, Phillip M, et al. Analysis of benefit:risk in the subgroup of patients with a BMI of ≥ 27 kg/m2 in the dapagliflozin DEPICT-1 and -2 trials in type 1 diabetes [abstract no. 7914 plus poster]. In: Endocrine Society Annual Meeting. 2019.Google Scholar
- 35.AstraZeneca. Update on US regulatory decision for Farxiga in type-1 diabetes [media release]. 15 Jul 2019. https://www.astrazeneca.com/.
- 36.Lexicon Pharmaceuticals. FDA issues complete response letter for Zynquista (sotagliflozin) [media release]. 22 Mar 2019. http://www.lexpharma.com.
- 40.National Institute for Health and Care Excellence. Dapagliflozin with insulin for treating type 1 diabetes: final appraisal document. 2019. https://www.nice.org/uk. Accessed 27 Sep 2019.
- 41.Bennett H, McEwan P, Evans M, et al. Cost-effectiveness of dapagliflozin in adult patients with inadequately controlled type 1 diabetes: a health economic analysis using 24-week results from the DEPICT-1 randomised controlled trial [abstract no. DB4]. Value Health. 2018;21(Suppl 3):S7.Google Scholar